Oric Pharmaceuticals ORIC 深 滬
等待開盤 10-31 09:30:00 美东时间
13.34
+0.410
+3.17%
華盛通- 最 高13.51
- 今 開12.752
- 成交量 90.86万股
- 最 低 12.752
- 昨 收 12.93
- 總市值 12.96亿
- 52周最高 14.93
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.8951
- 委 比 58.08%
- 總股本 9712.30万
- 歷史最高 40.81
- 量 比 0.79
- 振 幅 5.86%
- 歷史最低 2.36
- 每 手 1
- 風險率 2.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ORIC Pharmaceuticals Highlights Preclinical Data At EORTC-NCI-AACR Supporting ORIC-944's Potential For Prostate And Solid Tumor Treatment
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International
10-27 20:41
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
ORIC Pharmaceuticals presented preclinical data on ORIC-944, a PRC2 inhibitor targeting prostate cancer and solid tumors, at the 2025 EORTC-NCI-AACR Conference. The data highlight ORIC-944's potential to overcome resistance when combined with AR or KRAS inhibitors, showing improved efficacy and prolonged responses in preclinical models. ORIC-944 demonstrated best-in-class properties and favorable safety profiles in ongoing trials. ORIC continues ...
10-27 12:30
Guggenheim Assumes ORIC Pharmaceuticals at Buy, Announces Price Target of $18
Guggenheim analyst Brad Canino assumes ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $18.
09-04 22:12
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
ORIC Pharmaceuticals任命Kevin Brodbeck博士为首席技术官，以应对即将到来的多期临床试验。Brodbeck博士在制药行业拥有25年经验，曾领导多个关键部门，包括CMC和质量保证。ORIC的临床项目预计将于2026年进入三期试验阶段。Brodbeck博士的加入标志着公司向后期开发迈进的重要一步。
08-18 20:05
INTEGRA AND SHOSHONE-PAIUTE TRIBES ESTABLISH HISTORIC RELATIONSHIP AGREEMENT
TSXV: ITR; NYSE American: ITRG www.integraresources.com VANCOUVER, BC, Aug. 15, 2025 /PRNewswire/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV: ITR) (NYSE American: ITRG) is ...
08-15 18:00
Guggenheim Reiterates Buy on ORIC Pharmaceuticals, Maintains $18 Price Target
Guggenheim analyst Michael Schmidt reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $18 price target.
08-13 21:38
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
ORIC Pharmaceuticals reported promising clinical efficacy and safety data for ORIC-944 in treating metastatic castration-resistant prostate cancer and presented updated financial results. The company strengthened its cash position with $244 million in proceeds from private placement and ATM issuances, enabling a revised operating plan to extend its cash runway into 2H 2028. ORIC prioritized its lead programs, ORIC-944 and enozertinib, and announc...
08-12 20:05
PARAMOUNT AND TKO ANNOUNCE HISTORIC UFC MEDIA RIGHTS AGREEMENT
PARAMOUNT TO BECOME EXCLUSIVE HOME OF UFC IN THE U.S. Beginning in 2026, all UFC numbered events and Fight Nights will stream live on Paramount+, with select marquee fights simulcast on CBS ...
08-11 20:00
美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
Ladenburg Thalmann Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $15
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $15.
07-09 02:47
